ClinicalTrials.gg
CompletedNCT00630825EGOUpdated Dec 10, 2014Results posted

A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus Type 2, sponsored by Eli Lilly and Company. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-10.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
24th of 54
262 · median 159
Started
2008
with 2 others
Phase 2
5 of 54
none open now
Registered
1st of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 24th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus >3 months by history prior to entering the trial, based on disease diagnostic criteria from the American Diabetes Association (ADA 2007).
  • Men or women 18 years of age or older. Women must have a negative pregnancy test and be willing to use during study duration and one month post.
  • Have glycosylated () of >7.0% to ≤10.5% as determined by central laboratory at screening.
  • Have a (BMI) between 27 and 40 kilograms/meter squared (kg/m\^2), inclusive.
  • Have been on the same doses for 3 months of any approved combination of 2 oral antihyperglycemic medications in any combination of the following: sulfonylureas (e.g. Chlorpropamide or Diabinese, Glimepiride or Amaryl, Tolbutamide or Orinase, Tolazamide or Tolinase, Glipizide or Glucotrol, Glyburide also known as Micronase, Diabeta, or Glynase), biguanides (e.g. Glucophage or metformin), thiazolidinediones (e.g. Rosiglitazone or Avandia, or Pioglitazone or Actos), or dipeptidyl peptidase 4 (DPP-IV) inhibitors (e.g. Sitagliptin or Januvia). A combination pill of any 2 of these drugs is allowed (1 only), (e.g. Metformin and Glipizide or Metaglip), (e.g. Metformin and Glyburide or Glucovance), (e.g. Pioglitazone and Glimepiride or Duetact), or (e.g. Sitagliptin and Metformin or Janumet).

Exclusion criteria

Exclusion Criteria:

  • Have known Type 1 Diabetes Mellitus
  • Have taken glucagon-like peptide-1 (GLP-1) or any GLP-1 analog drug (Byetta)
  • Have a history of unstable angina, heart attack (myocardial infarction), heart arrhythmia (ventricular), congestive heart failure, or other coronary intervention (percutaneous transluminal coronary angioplasty [PTCA], open heart surgery, or coronary artery bypass graft [CABG]), a (TIA) or stroke (cerebrovascular accident) in the last 6 months prior to screening.
  • Have acute or chronic hepatitis or elevated liver function tests (), a history of chronic or recurrent pancreatitis. Have renal disease or a serum creatinine (blood test) >2 milligrams per deciliter (mg/dL). If taking biguanides (e.g. metformin or Glucophage), or DPP-IV inhibitors (e.g. Sitagliptin or Januvia or Janumet), creatinine must be ≤1.5 mg/dL.
  • Currently taking prescription or over the counter medications to prevent weight loss.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    1.0/2.0 milligram (mg) LY2189265

    LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks

    Drug: LY2189265

  • Experimental
    1.0/1.0 milligram (mg) LY2189265

    LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks

    Drug: LY2189265

  • Experimental
    0.5/1.0 milligram (mg) LY2189265

    LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks

    Drug: LY2189265

  • Placebo comparator
    Placebo

    Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks

    Drug: Placebo

Interventions

  • Also known as: Dulaglutide

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus

    Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).

    Time frame: Baseline, 16 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Blood Glucose

    Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

    Time frame: Baseline, 16 weeks

  2. Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)

    Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie \[Kcal\], 103 grams \[g\] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting \[0\]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.

    Time frame: Baseline and 16 weeks

  3. Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles

    Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

    Time frame: 2 separate days in the week preceding the Baseline, Week 4, Week 8, and Week 16 visits.

  4. Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)

    Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.

    Time frame: Baseline, 16 weeks

  5. Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%

    Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.

    Time frame: Baseline and 4 and 8 and 16 weeks

  6. Change From Baseline in Body Weight

    LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

    Time frame: Baseline, 4, 8, and 16 weeks

  7. Change From Baseline in Waist Circumference

    Mean change from baseline in waist circumference (a measure of central obesity).

    Time frame: Baseline, 16 weeks

  8. Nausea and Dyspepsia Measured by Visual Analog Scale

    Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.

    Time frame: One week before and one week after each of the Baseline and Week 4 and Week 8 and Week 16 visits

  9. Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores

    Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.

    Time frame: Baseline and 4 and 8 and 16 weeks

  10. Number of Participants With a Hypoglycemic Event

    A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of \<50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 4, 8, and 16 weeks

  11. Rate of Hypoglycemia Per 30 Days

    Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 16 weeks

  12. Change From Baseline in Lipids

    Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.

    Time frame: Baseline, 16 weeks

  13. Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire

    The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6-point scale ranging from 1 "completely dissatisfied" to 6 "completely satisfied"; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time"; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time." These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.

    Time frame: Baseline and 4 and 8 and 16 weeks

  14. Validation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire

    This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.

    Time frame: Baseline and 4 and 8 and 16 weeks

  15. Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)

    The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration).

    Time frame: Time zero to 168 hours after study drug administration at 4, 8, and 16 weeks

07

Results

Posted Dec 10, 2014

Participant flow

Participant flow — Overall Study
Milestone1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Started65656666
Received at least one dose of study drug65656666
Completed56585860
Not completed9786
Withdrew: Adverse event4431
Withdrew: Entry criteria not met1021
Withdrew: Lost to follow-up1111
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject2223

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).

Time frame:
Baseline, 16 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus
percentage of glycosylated hemoglobin1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus-1.52 ± 0.12-1.29 ± 0.12-1.28 ± 0.12-0.27 ± 0.12
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryChange From Baseline in Fasting Blood Glucose

Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

Time frame:
Baseline, 16 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline in Fasting Blood Glucose
millimoles per liter (mmol/L)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Change From Baseline in Fasting Blood Glucose-2.64 ± 0.33-2.04 ± 0.34-2.09 ± 0.34-0.49 ± 0.32
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryMeal Test Glucose Excursion (Change in Blood Glucose to Test Meal)

Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie \[Kcal\], 103 grams \[g\] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting \[0\]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.

Time frame:
Baseline and 16 weeks
Reported as:
Mean · millimoles per liter (mmol/L)*minute
Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)
millimoles per liter (mmol/L)*minute1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Baseline (n=63, n=62, n=66, n=63)11.03 ± 5.0211.12 ± 4.7710.32 ± 4.9310.76 ± 4.37
Week 16 (n=52, n=56, n=54, n=59)8.16 ± 4.589.92 ± 5.328.85 ± 4.9410.94 ± 4.79
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.047 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.025 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryChange From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles

Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

Time frame:
2 separate days in the week preceding the Baseline, Week 4, Week 8, and Week 16 visits.
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles
milligrams per deciliter (mg/dL)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Week 4 (n=34, n=38, n=35, n=41)-31.19 ± 5.85-35.94 ± 5.30-31.66 ± 5.36-8.10 ± 5.06
Week 8 (n=34, n=41, n=38, n=41)-43.00 ± 5.88-40.68 ± 5.43-36.02 ± 5.35-14.58 ± 5.38
Week 16 (n=41, n=50, n=46, n=49)-37.49 ± 5.89-41.79 ± 5.25-32.52 ± 5.40-8.67 ± 5.30
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryChange From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)

Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.

Time frame:
Baseline, 16 weeks
Reported as:
Mean · percentage of HOMA2
Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)
percentage of HOMA21.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
HOMA2-%B45.61 ± 55.2044.26 ± 93.8939.20 ± 45.561.04 ± 41.12
HOMA2-%S3.58 ± 18.51-1.65 ± 17.190.46 ± 13.782.46 ± 12.23
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.004 (Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.904 (Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.138Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.729 (Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryPercentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%

Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.

Time frame:
Baseline and 4 and 8 and 16 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%
percentage of participants1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
HbA1c levels <7.0%, Baseline3.14.61.54.5
HbA1c levels ≤6.5%, Baseline0.01.50.00.0
HbA1c levels <7.0%, Week 415.430.822.77.6
HbA1c levels ≤6.5%, Week 44.67.73.01.5
HbA1c levels <7%, Week 841.547.747.015.2
HbA1c levels ≤6.5%, Week 820.026.218.21.5
HbA1c levels <7%, Week 1653.850.856.115.2
HbA1c levels ≤6.5%, Week 1632.332.333.34.5
SecondaryChange From Baseline in Body Weight

LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.

Time frame:
Baseline, 4, 8, and 16 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
4 weeks (n=63, n=63, n=65, n=65)-1.28 ± 0.23-1.08 ± 0.23-0.50 ± 0.22-0.06 ± 0.22
8 weeks (n=61, n=60, n=63, n=64)-2.12 ± 0.31-1.67 ± 0.32-1.39 ± 0.31-0.12 ± 0.31
16 weeks (n=63, n=63, n=65, n=65)-2.51 ± 0.38-1.40 ± 0.38-1.58 ± 0.37-0.07 ± 0.38
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.113 (Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = <0.001 (Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.004 (Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.001 (Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryChange From Baseline in Waist Circumference

Mean change from baseline in waist circumference (a measure of central obesity).

Time frame:
Baseline, 16 weeks
Reported as:
Mean · centimeters (cm)
Change From Baseline in Waist Circumference
centimeters (cm)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Change From Baseline in Waist Circumference-1.92 ± 4.24-1.51 ± 4.56-1.33 ± 4.210.20 ± 3.40
Statistical analysis
  • 1.0/2.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.009 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 1.0/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.028 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
  • 0.5/1.0 Milligram (mg) LY2189265 vs Placebo · ANCOVA · p = 0.047 (P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.)
SecondaryNausea and Dyspepsia Measured by Visual Analog Scale

Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.

Time frame:
One week before and one week after each of the Baseline and Week 4 and Week 8 and Week 16 visits
Reported as:
Mean · units on a scale
Nausea and Dyspepsia Measured by Visual Analog Scale
units on a scale1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Nausea, Week before Baseline (n=52, 57, 61, 57)4.81 ± 10.503.56 ± 6.463.70 ± 5.763.35 ± 5.83
Nausea, Week after Baseline (n=42, 46, 50, 50)5.07 ± 8.583.85 ± 6.463.86 ± 5.962.25 ± 4.82
Ab pain, Week before Baseline (n=52, 57, 61, 57)5.66 ± 11.373.55 ± 9.144.04 ± 7.153.63 ± 6.58
Ab pain, Week after Baseline (n=42, 46, 50, 50)5.82 ± 9.414.89 ± 13.354.51 ± 8.602.86 ± 7.27
Bloating, Week before Baseline (n=52, 57, 61, 57)11.49 ± 16.808.11 ± 18.0410.21 ± 15.329.30 ± 18.65
Bloating, Week after Baseline (n=42, 46, 50, 50)8.95 ± 12.9010.10 ± 16.649.17 ± 15.618.42 ± 20.05
Nausea, Week before Week 4 (n=42, 55, 52, 59)6.74 ± 10.896.88 ± 11.477.97 ± 15.334.10 ± 7.32
Nausea, Week after Week 4 (n=49, 58, 59, 54)18.13 ± 24.5212.28 ± 19.467.91 ± 12.394.10 ± 7.57
Ab pain, Week before Week 4 (n=42, 55, 52, 59)6.28 ± 9.537.74 ± 13.896.38 ± 11.134.45 ± 9.19
Ab pain, Week after Week 4 (n=49, 58, 59, 54)12.47 ± 20.449.31 ± 15.774.94 ± 8.894.59 ± 7.88
Bloating, Week before Week 4 (n=42, 55, 52, 59)13.56 ± 19.5112.00 ± 19.179.95 ± 13.277.96 ± 15.77
Bloating, Week after Week 4 (n=49, 58, 59, 54)19.90 ± 25.6113.40 ± 21.1510.23 ± 13.888.40 ± 14.96
Nausea, Week before Week 8 (n=50, 51, 55, 58)10.90 ± 20.265.45 ± 10.637.39 ± 13.536.11 ± 12.59
Nausea, Week after Week 8 (n=50, 54, 54, 55)8.58 ± 12.885.57 ± 11.508.69 ± 13.415.30 ± 11.52
Ab pain, Week before Week 8 (n=50, 51, 55, 58)10.76 ± 19.065.76 ± 12.475.12 ± 9.016.65 ± 13.15
Ab pain, Week after Week 8 (n=50, 54, 54, 55)7.97 ± 14.726.87 ± 14.566.26 ± 11.936.38 ± 12.74
Bloating, Week before Week 8 (n=50, 51, 55, 58)17.65 ± 26.4110.93 ± 17.9211.58 ± 20.1310.12 ± 19.20
Bloating, Week after Week 8 (n=50, 54, 54, 55)13.30 ± 18.6611.18 ± 19.5614.50 ± 20.9510.34 ± 17.17
Nausea, Week before Week 16 (n=45, 49, 52, 54)9.68 ± 17.793.31 ± 5.536.36 ± 10.825.88 ± 14.41
Nausea, Week after Week 16 (n=45, 48, 49, 53)11.09 ± 17.625.73 ± 10.807.77 ± 12.253.40 ± 6.40
Ab pain, Week before Week 16 (n=45, 49, 52, 54)6.46 ± 9.485.68 ± 11.096.26 ± 12.896.17 ± 14.24
Ab pain, Week after Week 16 (n=45, 48, 49, 53)7.56 ± 14.285.99 ± 11.536.44 ± 12.585.19 ± 11.72
Bloating, Week before Week 16 (n=45, 49, 52, 54)12.57 ± 18.939.06 ± 16.7812.26 ± 20.069.30 ± 18.60
Bloating, Week after Week 16 (n=45, 48, 49, 53)14.06 ± 20.4611.11 ± 19.6214.04 ± 22.268.84 ± 17.44
SecondaryChange From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores

Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.

Time frame:
Baseline and 4 and 8 and 16 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores
units on a scale1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Stomach fullness, Week 4 (n=62, n=60, n=65, n=65)0.55 ± 1.510.57 ± 1.350.62 ± 1.260.35 ± 1.39
Stomach fullness, Week 8 (n=59, n=60, n=59, n=63)0.46 ± 1.650.30 ± 1.330.71 ± 1.540.25 ± 1.39
Stomach fullness, Week 16 (n=63, n=62, n=65, n=65)0.21 ± 1.580.27 ± 1.280.51 ± 1.340.15 ± 1.34
Bloating, Week 4 (n=62, n=60, n=65, n=65)0.35 ± 0.100.28 ± 0.930.19 ± 0.910.28 ± 0.84
Bloating, Week 8 (n=59, n=60, n=60, n=63)0.41 ± 1.340.13 ± 1.020.14 ± 1.320.18 ± 0.92
Bloating, Week 16 (n=63, n=62, n=65, n=65)0.02 ± 1.040.11 ± 0.940.32 ± 1.320.28 ± 0.86
Nausea/Vomiting, Week 4 (n=62, n=60, n=64, n=65)0.25 ± 0.710.19 ± 0.710.22 ± 0.520.03 ± 0.40
Nausea/Vomiting, Week 8 (n=59, n=60, n=60, n=63)0.46 ± 0.970.04 ± 0.640.28 ± 0.620.02 ± 0.39
Nausea/Vomiting, Week 16 (n=63, n=62, n=65, n=65)0.20 ± 0.64-0.01 ± 0.590.27 ± 0.48-0.01 ± 0.36
SecondaryNumber of Participants With a Hypoglycemic Event

A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of \<50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 4, 8, and 16 weeks
Reported as:
Number · participants
Number of Participants With a Hypoglycemic Event
participants1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Documented Hypoglycemic Event, Week 41717179
Documented Hypoglycemic Event, Week 811131510
Documented Hypoglycemic Event, Week 1661078
Severe Hypoglycemic Event, Week 40000
Severe Hypoglycemic Event, Week 80000
Severe Hypoglycemic Event, Week 160000
SecondaryRate of Hypoglycemia Per 30 Days

Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 16 weeks
Reported as:
Mean · events per participant per 30 days
Rate of Hypoglycemia Per 30 Days
events per participant per 30 days1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Rate of Hypoglycemia Per 30 Days0.69 ± 1.290.80 ± 1.600.70 ± 1.180.24 ± 0.54
SecondaryChange From Baseline in Lipids

Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.

Time frame:
Baseline, 16 weeks
Reported as:
Median · millimoles per liter (mmol/L)
Change From Baseline in Lipids
millimoles per liter (mmol/L)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Cholesterol (n=61, n=60, n=60, n=62)-0.34 (-3.44 to 2.28)-0.05 (-1.37 to 2.69)-0.09 (-2.18 to 4.77)0.18 (-1.91 to 2.56)
LDL-Cholesterol (n=61, n=60, n=60, n=61)-0.26 (-2.80 to 2.23)-0.09 (-1.22 to 1.58)-0.07 (-1.39 to 4.27)0.10 (-0.83 to 2.12)
HDL-Cholesterol (n=61, n=60, n=60, n=61)-0.02 (-0.33 to 0.41)-0.02 (-0.37 to 0.54)0.00 (-0.26 to 0.23)0.00 (-0.24 to 0.26)
Triglycerides (n=61, n=60, n=60, n=61)-0.16 (-7.63 to 2.22)-0.02 (-4.84 to 2.96)-0.16 (-4.25 to 2.96)0.00 (-7.39 to 5.69)
SecondaryParticipants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire

The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6-point scale ranging from 1 "completely dissatisfied" to 6 "completely satisfied"; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time"; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time." These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.

Time frame:
Baseline and 4 and 8 and 16 weeks
Reported as:
Number · percentage of participants
Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire
percentage of participants1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
Baseline72.787.087.589.1
Week 483.390.287.587.0
Week 882.990.590.988.6
Week 1692.190.286.093.0
SecondaryValidation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire

This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.

Time frame:
Baseline and 4 and 8 and 16 weeks

No measurements were reported for this outcome.

SecondaryPharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)

The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration).

Time frame:
Time zero to 168 hours after study drug administration at 4, 8, and 16 weeks
Reported as:
Mean · nanograms*hour/milliliter (ng*h/mL)
Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)
nanograms*hour/milliliter (ng*h/mL)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265
Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)14587 ± 56747876 ± 30644488 ± 1746

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.0/2.0 Milligram (mg) LY2189265—1/65 (1.5%)41/65 (63.1%)
1.0/1.0 Milligram (mg) LY2189265—2/65 (3.1%)35/65 (53.8%)
0.5/1.0 Milligram (mg) LY2189265—3/66 (4.5%)40/66 (60.6%)
Placebo—1/66 (1.5%)36/66 (54.5%)
Most frequent serious events
Most frequent serious events
Event1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
PneumoniaInfections and infestations1/650/650/661/66
OsteoarthritisMusculoskeletal and connective tissue disorders0/651/650/660/66
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/651/650/660/66
PancreatitisGastrointestinal disorders0/650/651/660/66
Septic shockInfections and infestations0/650/650/661/66
HallucinationPsychiatric disorders0/650/651/660/66
Cryptogenic organising pneumoniaRespiratory, thoracic and mediastinal disorders0/650/651/660/66
Most frequent other events
Showing 10 of 18
Most frequent other events
Event1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265Placebo
NauseaGastrointestinal disorders9/6511/659/665/66
Abdominal distensionGastrointestinal disorders9/655/653/664/66
DiarrhoeaGastrointestinal disorders9/654/655/665/66
VomitingGastrointestinal disorders7/651/653/662/66
ConstipationGastrointestinal disorders6/653/656/660/66
NasopharyngitisInfections and infestations5/654/652/663/66
Abdominal painGastrointestinal disorders4/652/655/663/66
Abdominal pain upperGastrointestinal disorders4/653/652/662/66
Upper respiratory tract infectionInfections and infestations0/650/651/664/66
Early satietyGeneral disorders0/653/651/660/66

Baseline characteristics

Participants who received at least one dose of LY2189265 or Placebo.

Age, Continuous
Age, Continuous(years)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Mean54.49 ± 11.2857.46 ± 11.7258.65 ± 11.6955.96 ± 12.4956.65 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Female31303137129
Male34353529133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
African465419
Caucasian36394036151
East Asian10001
Hispanic2320192688
Native American10203
Region of Enrollment
Region of Enrollment(participants)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
United States56565758227
Puerto Rico999835
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Mean8.43 ± 0.998.25 ± 0.998.25 ± 0.898.05 ± 0.828.24 ± 0.93
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meters (kg/m^2))1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Mean34.24 ± 4.1133.85 ± 3.9533.70 ± 4.1133.89 ± 4.3133.92 ± 4.10
Body Weight
Body Weight(kilograms (kg))1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Mean98.60 ± 18.4196.68 ± 16.5194.76 ± 16.5394.74 ± 15.2196.18 ± 16.68
Duration of Diabetes
Duration of Diabetes(years)1.0/2.0 Milligram (mg) LY21892651.0/1.0 Milligram (mg) LY21892650.5/1.0 Milligram (mg) LY2189265PlaceboTotal
Mean8.63 ± 6.928.13 ± 5.438.97 ± 7.627.48 ± 5.418.30 ± 6.41
08

Study locations

34 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Arizona 85381, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92805, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Northridge, California 91326, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Springs, California 92262, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Miami, Florida 33143, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Georgia 30606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46250, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Biddeford, Maine 04005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48108, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomfield Hills, Michigan 48302, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Flemington, New Jersey 08822, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Syracuse, New York 13210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greensboro, North Carolina 27401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, North Carolina 27834, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morehead City, North Carolina 28557, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norfolk, Virginia 23510, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Renton, Washington 98057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenatchee, Washington 98801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Menomonee Falls, Wisconsin 53051, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manatí, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00907, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toa Baja, 00949, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 5 years 11 months after primary completion. A results delay was requested in Dec 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2008
First posted
Mar 7, 2008
Start
Apr 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results delay requested
Dec 9, 2009
Results first posted
Dec 10, 2014
Last update
Dec 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00630825
Responsible party
Sponsor
First posted
Mar 7, 2008
Start date
Apr 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Dec 10, 2014
Last update
Dec 10, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion